How do you decide between the gene silencing drugs for familial amyloidosis with polyneuropathy?

The data to answer this question are very limited to non-existent, exactly because there have been no studies with a head-to-head comparison of the efficacy of different agents. Ultimately, it's a shared decision between the patient and the physician, which should take into account factors such as patient convenience and preference. Vutisiran and eplontersen are probably the most convenient choices, as they are administered subcutaneously every 3 months (vutisiran) or monthly (eplontersen). Inot...